NEW YORK – Gestalt Diagnostics and Deep Bio announced on Wednesday a strategic relationship to develop an integrated workflow to use artificial intelligence algorithms on Gestalt's digital pathology platform.
South Korea-based Deep Bio's DeepDx Prostate algorithm analyzes whole slide images of hematoxylin and eosin-stained prostate core needle biopsy tissue specimens to detect and classify prostate cancer, Gleason scores, and grade group.
The partnership will provide pathologists "with instant access to AI algorithms directly within their workflow," Lisa-Jean Clifford, Gestalt's COO and chief strategy officer, said in a statement. That access "presents them with key data in real time, shortening the time to diagnosis for cancer patients," she added.
Gestalt's PathFlow platform is an enterprise software platform that was originally used as a digital reading platform for radiology but has been expanded and redesigned to work for pathologists, the company said in a statement.
Financial and other terms of the deal were not disclosed.